Loading...
XSHG
600276
Market cap44bUSD
Apr 03, Last price  
51.04CNY
1D
0.37%
1Q
15.06%
Jan 2017
74.99%
Name

Jiangsu Hengrui Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
P/E
75.32
P/S
14.20
EPS
0.68
Div Yield, %
0.39%
Shrs. gr., 5y
-0.33%
Rev. gr., 5y
5.55%
Revenues
22.82b
+7.26%
1,145,143,6191,179,259,5571,422,456,9041,959,660,1212,392,561,1593,028,960,8813,744,106,2694,550,391,7685,435,067,5616,203,074,3557,452,253,0879,315,960,16811,093,724,12113,835,629,36917,417,901,05023,288,576,60727,734,598,74725,905,526,37521,275,270,68122,819,784,741
Net income
4.30b
+10.14%
122,620,494162,222,057206,647,797412,921,287422,947,064665,730,889724,173,302876,611,0611,077,384,7641,238,110,6351,515,568,8632,171,571,5452,588,952,0953,216,647,9984,065,609,7165,328,027,5196,328,383,2194,530,217,5503,906,375,0674,302,435,930
CFO
7.64b
+504.12%
209,412,777227,876,230266,175,427218,873,724117,459,736439,116,229385,945,810527,357,720958,368,8911,364,958,6661,574,306,0242,277,293,1222,592,628,3952,547,385,4162,774,212,7343,816,832,8673,431,934,8054,218,816,0531,265,264,6317,643,665,074
Dividend
Jul 12, 20240.2 CNY/sh
Earnings
Apr 16, 2025

Profile

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
URL
https://www.hengrui.com/
IPO date
Oct 18, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
22,819,785
7.26%
21,275,271
-17.87%
Cost of revenue
18,342,513
17,471,868
Unusual Expense (Income)
NOPBT
4,477,271
3,803,403
NOPBT Margin
19.62%
17.88%
Operating Taxes
389,289
153,421
Tax Rate
8.69%
4.03%
NOPAT
4,087,982
3,649,982
Net income
4,302,436
10.14%
3,906,375
-13.77%
Dividends
(1,019,873)
(1,014,797)
Dividend yield
0.36%
0.41%
Proceeds from repurchase of equity
(827,265)
(398,028)
BB yield
0.29%
0.16%
Debt
Debt current
1,260,943
Long-term debt
150,353
197,721
Deferred revenue
38,950
119,440
Other long-term liabilities
Net debt
(22,047,134)
(16,412,510)
Cash flow
Cash from operating activities
7,643,665
1,265,265
CAPEX
(1,483,792)
Cash from investing activities
1,222,315
390,289
Cash from financing activities
(3,144,426)
FCF
6,711,230
1,591,918
Balance
Cash
20,845,155
17,871,175
Long term investments
1,352,332
Excess cash
21,056,498
16,807,411
Stockholders' equity
35,768,386
35,424,979
Invested Capital
20,090,715
22,965,808
ROIC
18.99%
17.31%
ROCE
10.86%
9.54%
EV
Common stock shares outstanding
6,327,112
6,367,002
Price
45.23
17.39%
38.53
-24.02%
Market cap
286,175,260
16.65%
245,320,590
-24.18%
EV
264,695,417
229,497,428
EBITDA
5,181,907
4,381,296
EV/EBITDA
51.08
52.38
Interest
6,655
6,492
Interest/NOPBT
0.15%
0.17%